



Policy Updates – First Quarter 2024

NEW DRUG SPECIFIC POLICIES *Effective 4/1/2024*

Casgevvy™ (exagamglogene autotemcel)	iDose® TR (travoprost intracameral implant)	Ryzneuta® (efbemalenograstim alfavuxw)
Filsuvez (birch triterpenes) topical gel	Lyfgenia® (lovotibeglogene autotemcel)	Zelsuvmi™ (berdazimer) topical gel
	Ogsiveo (nirogacestat)	

EXISTING DRUG SPECIFIC POLICIES WITH CLINICAL CHANGES *Effective 4/1/2024*

Adbry (tralokinumab-ldrm)	Dupixent	Lupkynis
Afrezza	Evkeeza	Nuzyra (omadacycline)
Alecensa	Growth Hormone <i>effective 1/1/2024</i>	Opsumit
Apretude		Prevymis
Beyfortus	Growth Hormone State Plans <i>effective 1/1/2024</i>	Sildenafil (Applies to Revatio and Liqrev)
Biologic Drugs (for Auto-Immune Diseases-In Office Admin) <i>effective 2/1/2024</i>	Infliximab (Applies to Remicade, Renflexis, Inflectra and Avsola) <i>effective 2/1/2024</i>	Strensiq
Cometriq		Tadalafil
Cotellic	Implantable Testosterone Products (Applies to Testopel)	Tarpeyo
Direct Renin Inhibitor: (Applies to aliskiren fumarate)	Jaypirca	Tezspire
	Lemtrada	Xalkori
		Ycanth
		Zurzuvae

EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES *Effective 4/1/2024*

Abilify MyCite	Besremi	Cipro HC
Adempas	Bethkis	Ciprodex
Alunbrig	Biosimilar Medications	CNS Stimulants Drug Utilization Review
Amifampridine – Applies to Firdapse (previously named Amifampridine – Applies to Firdapse and Ruzurgi)	Blood Glucose Meters	Dextenza
	C-1 Esterase Inhibitors	Duexis
	Cabometyx	Epaned
Arikayce	Caplyta	Esbriet
Aveed	Cibinqo	Ferriprox

Filgrastim	MS Disease Modifying	Tazverik
Fragmin and Arixtra	Nexavar	Tegsedi
Gleevec (imatinib mesylate)	Nitisinone	Testosterone Topical
Iclusig	Ofev	Valchlor Gel
Idhifa	Pegasys	Varubi
Increlex	Phexxi	Verquvo
Infliximab	Quviviq	Vibrant
Juxtapid	Rayos	Vitrakvi
Keveyis	Recorlev	Xermelo
LABA (Serevent) Step Therapy	Regranex	Zelboraf
Letairis	Rinvoq	Zyflo
Livtencity	Targretin capsules	
	Targretin gel	

EXISTING DRUG SPECIFIC POLICIES REVIEW ONLY/NO CHANGES

Adstiladrin	Growth Hormone-State Plans	Repository Corticotropin Gel
Aristada	Hemgenix	Revcovi
Avycaz	Injectable Medications for the Sole Purpose of Inducing Pregnancy	Rezlidhia
Ayvakit		Susvimo
Bosulif	Intra-articular Injections of Hyaluronate Products	Tysabri and Tyruko
Botulinum Toxin (applies to: Botox™, Daxxify, Dysport™, Myobloc™ Xeomin)	IDPN	Tzield
Briumvi	Kimmtrak	Vabysmo
Cabenuva	Krazati	Votrient
Diabetic Supply	Krystexxa	Voxzogo
Duchenne Muscular Dystrophy Drugs- State Products	Leqembi	Vyepti
Elahere	Leqembi FEHB	Vyvgart
Enjaymo	Leqvio	Vyzulta
Enteral Formula	Lunsumio	Xgeva
Gamifant	NPlate	Xiidra
Gender Dysphoria Treatment State Plans	Ocrevus	Yupelri
	Orserdu	Zilretta
	Royaldee	
	Rebyota	

NEW ADMINISTRATIVE POLICIES

In-Patient Drug Review

EXISTING ADMINISTRATIVE POLICIES WITH CHANGES

Maintenance Drug Policy

Oncology Drug Management

Overview of Pharmacy Benefit

P&T Committee Integrity Policy

Retail Maintenance Medication

EXISTING ADMINISTRATIVE POLICIES REVIEW ONLY/NO CHANGES

Potential Fraud and Abuse of Controlled Substances

POLICIES TO BE ARCHIVED

Daurismo	Lorbrena	Talzenna
Daliresp	Lynparza	Tepmetko
Erivedge	Nerlynx	Ultracet
Gilotrif	Ninlaro	Venclexta
Ibrance	Odomzo	Vizimpro
Inlyta	Orgovyx	Xospata
Iressa	Pomalyst	Xtandi
Kisqali	Rydapt	Zejula
Lenvima	Stivarga	Zydelig
Lonsurf	Synribo	Zykadia

PBD ONLY NEW DRUG SPECIFIC POLICIES Effective 4/1/2024

Daurismo	Lenvima	Rydapt
Erivedge	Lonsurf	Talzenna
Gilotrif	Lorbrena	Tepmetko
Ibrance	Lynparza	Vizimpro
Inlyta	Nerlynx	Zejula
Iressa	Ninlaro	
Kisquali	Orgovyx	

PBD EXISTING DRUG SPECIFIC POLICIES WITH CLINICAL CHANGES Effective 4/1/2024

BDAID in office (effective 2/1/2024)	Infliximab (effective 2/1/2024)	Jakafi
		Odomzo

Pomalyst	Xospata	Zykadia
Stivarga	Xtandi	
Venclexta	Zydelig	

PBD EXISTING DRUG SPECIFIC POLICIES REVIEW ONLY/NO CHANGES

Promacta
Zolinza

PBD EXISTING ADMINISTRATIVE POLICIES REVIEW ONLY/NO CHANGES

PBD Step Therapy Exception Policy

PBD NEW ADMINISTRATIVE POLICY

Experimental and Investigational treatment

Magellan RX Management Drug Specific Policies

Jakafi (ruxolitinib)

Magellan RX Management Drug Specific Custom Policy Updates Effective 1/1/2024

Orencia® (abatacept)

Magellan RX Management Drug Specific Custom Policy Updates Effective 2/1/2024

Infliximab: Remicade®; Inflectra®; Renflexis™; Avsola®; Infliximab

Existing Magellan RX Management Drug Specific Policies w/Clinical Changes

Medical PA Only (effective 2/2/2024)

Aliqopa	Keytruda	Vabysmo
Bortezomib	Libtayo	Vectibix
Besponsa	Mylotarg	Vyvgart_IV
Fulvestrant	Opdivo	
Jemperli	Tecentriq	

Medical PA Only (effective 2/23/2024)

Adakveo	Givlaari	Pemetrexed
Adcetris	Imfinzi	Rituximab_IV
Bevacizumab_ONCO	Keytruda	Sylvant
Danyelza	Kyprolis	Synribo
Darzalex_IV	Nulibry	Tepezza
Factor VIII_vWF	Opdivo	Trastuzumab_IV
Erbitux	Oxlumo	Unituxin
Gamifant	Paclitaxel Albumin-Bound	Yervoy
Gazyva	Padcev	

Medical PA Only (effective 3/29/2024)

Aldurazyme	Lumizyme	Pegfilgrastim
Fabrazyme	Mepsevii	Revcovi
IVIG	Naglazyme	SCIG
Kanuma	Nexviazyme	Vimizim
Keytruda	Nplate	Vyvgart

Pharmacy PA Only (effective 2/2/2024)

Cosentyx	Qinlock	Xtandi
----------	---------	--------

Pharmacy PA Only (effective 2/23/2024)

Dasatinib	Lenvima
Eltrombopag	Welireg
Hycamtin_Oral	

Pharmacy PA Only (effective 3/29/2024)

Balversa	Mulpleta	Talzenna
Doptelet	Oxbryta	Tavalisse
Galafold		

PSCE only (effective 2/1/2024)

Doxorubicin liposomal
Eloxatin
Injectafer

Medical/Pharmacy (effective 2/2/2024)

Orencia
Ustekinumab (formally titled Stelara)